Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022.

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Bonhyang Na, Yu Jin Park, Jieun Seo, Miri Park, Jee Yeon Baek, Ji Young Lee, Minyoung Kim, Jong Gyun Ahn, Seung Tae Lee, Ji-Man Kang
{"title":"Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022.","authors":"Bonhyang Na, Yu Jin Park, Jieun Seo, Miri Park, Jee Yeon Baek, Ji Young Lee, Minyoung Kim, Jong Gyun Ahn, Seung Tae Lee, Ji-Man Kang","doi":"10.3346/jkms.2024.39.e206","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV), a highly transmissible virus, is the leading cause of lower respiratory tract infections. We examined molecular changes in the RSV genome before and after the coronavirus disease 2019 (COVID-19) pandemic in Korea, and investigated whether drug-resistant mutations were present.</p><p><strong>Methods: </strong>In this prospective, single-center study, RSV-positive respiratory samples were collected between September 2019 and December 2022. Long-read whole-genome sequencing (WGS) was performed, and the presence of known drug-resistant substitutions for palivizumab, nirsevimab, and suptavumab was investigated.</p><p><strong>Results: </strong>Overall, 288 respiratory samples were collected from 276 children. WGS data were available for 133 samples (71 and 62 samples from the pre- and post-pandemic periods, respectively). All RSV-A strains (n = 56) belonged to the GA2.3.5 (ON1) genotype, whereas all RSV-B strains (n = 77) belonged to the GB5.0.5a (BA) genotype. No significant differences in genotypes were observed between the pre- and post-pandemic periods. In addition, no notable mutations related to nirsevimab or palivizumab resistance were detected in the F gene. However, the L172Q and S173L substitutions, which are known to confer resistance to suptavumab, were present in all RSV-B samples.</p><p><strong>Conclusion: </strong>Despite the unprecedented interruption of RSV seasonality, there were no significant molecular changes in circulating RSV strains in Korea related to nirsevimab or palivizumab resistance before and after the COVID-19 pandemic. However, RSV-specific drug-resistance substitutions for suptavumab were identified.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":"39 28","pages":"e206"},"PeriodicalIF":3.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263766/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2024.39.e206","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Respiratory syncytial virus (RSV), a highly transmissible virus, is the leading cause of lower respiratory tract infections. We examined molecular changes in the RSV genome before and after the coronavirus disease 2019 (COVID-19) pandemic in Korea, and investigated whether drug-resistant mutations were present.

Methods: In this prospective, single-center study, RSV-positive respiratory samples were collected between September 2019 and December 2022. Long-read whole-genome sequencing (WGS) was performed, and the presence of known drug-resistant substitutions for palivizumab, nirsevimab, and suptavumab was investigated.

Results: Overall, 288 respiratory samples were collected from 276 children. WGS data were available for 133 samples (71 and 62 samples from the pre- and post-pandemic periods, respectively). All RSV-A strains (n = 56) belonged to the GA2.3.5 (ON1) genotype, whereas all RSV-B strains (n = 77) belonged to the GB5.0.5a (BA) genotype. No significant differences in genotypes were observed between the pre- and post-pandemic periods. In addition, no notable mutations related to nirsevimab or palivizumab resistance were detected in the F gene. However, the L172Q and S173L substitutions, which are known to confer resistance to suptavumab, were present in all RSV-B samples.

Conclusion: Despite the unprecedented interruption of RSV seasonality, there were no significant molecular changes in circulating RSV strains in Korea related to nirsevimab or palivizumab resistance before and after the COVID-19 pandemic. However, RSV-specific drug-resistance substitutions for suptavumab were identified.

利用全基因组测序对 COVID-19 大流行前后的呼吸道合胞病毒进行基因型分析:2019年至2022年韩国前瞻性单中心研究》。
背景:呼吸道合胞病毒(RSV)是一种传播性极强的病毒,是下呼吸道感染的主要病因。我们研究了韩国 2019 年冠状病毒病(COVID-19)大流行前后 RSV 基因组的分子变化,并调查了是否存在耐药突变:在这项前瞻性单中心研究中,在 2019 年 9 月至 2022 年 12 月期间收集了 RSV 阳性的呼吸道样本。进行了长线程全基因组测序(WGS),并调查了帕利珠单抗、尼尔赛维单抗和苏帕珠单抗是否存在已知的耐药替代:共收集了 276 名儿童的 288 份呼吸道样本。有 133 份样本(分别有 71 份和 62 份样本来自流行前和流行后)的 WGS 数据。所有 RSV-A 株系(n = 56)都属于 GA2.3.5 (ON1) 基因型,而所有 RSV-B 株系(n = 77)都属于 GB5.0.5a (BA) 基因型。在疫情流行前和疫情流行后,基因型没有明显差异。此外,在 F 基因中未发现与尼舍单抗或帕利珠单抗耐药性有关的明显突变。然而,在所有RSV-B样本中都出现了L172Q和S173L取代,而已知这两种取代可使患者对索帕珠单抗产生耐药性:结论:尽管RSV的季节性出现了前所未有的中断,但在COVID-19大流行前后,韩国循环中的RSV菌株与尼舍维单抗或帕利珠单抗耐药性有关的分子变化并不明显。不过,发现了RSV特异性耐药替代物苏妥珠单抗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Korean Medical Science
Journal of Korean Medical Science 医学-医学:内科
CiteScore
7.80
自引率
8.90%
发文量
320
审稿时长
3-6 weeks
期刊介绍: The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信